390 related articles for article (PubMed ID: 30470249)
1. A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer.
Zhao F; Olkhov-Mitsel E; Kamdar S; Jeyapala R; Garcia J; Hurst R; Hanna MY; Mills R; Tuzova AV; O'Reilly E; Kelly S; Cooper C; ; Brewer D; Perry AS; Clark J; Fleshner N; Bapat B
Clin Epigenetics; 2018 Nov; 10(1):147. PubMed ID: 30470249
[TBL] [Abstract][Full Text] [Related]
2. Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients.
Moreira-Barbosa C; Barros-Silva D; Costa-Pinheiro P; Torres-Ferreira J; Constâncio V; Freitas R; Oliveira J; Antunes L; Henrique R; Jerónimo C
Clin Epigenetics; 2018 Oct; 10(1):132. PubMed ID: 30373654
[TBL] [Abstract][Full Text] [Related]
3. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
Van Neste L; Partin AW; Stewart GD; Epstein JI; Harrison DJ; Van Criekinge W
Prostate; 2016 Sep; 76(12):1078-87. PubMed ID: 27121847
[TBL] [Abstract][Full Text] [Related]
4. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
[TBL] [Abstract][Full Text] [Related]
5. Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance.
Zhao F; Olkhov-Mitsel E; van der Kwast T; Sykes J; Zdravic D; Venkateswaran V; Zlotta AR; Loblaw A; Fleshner NE; Klotz L; Vesprini D; Bapat B
J Urol; 2017 Feb; 197(2):335-341. PubMed ID: 27545574
[TBL] [Abstract][Full Text] [Related]
6. Molecular Diagnostic of Prostate Cancer From Body Fluids Using Methylation-Specific PCR (MS-PCR) Method.
Minciu R; Dumache R; Gheorghe P; Daminescu L; Rogobete AF; Ionescu D
Clin Lab; 2016; 62(6):1183-6. PubMed ID: 27468582
[TBL] [Abstract][Full Text] [Related]
7. A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA.
Brikun I; Nusskern D; Decatus A; Harvey E; Li L; Freije D
Clin Epigenetics; 2018; 10():91. PubMed ID: 29988684
[TBL] [Abstract][Full Text] [Related]
8. Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer.
Leyten GH; Hessels D; Smit FP; Jannink SA; de Jong H; Melchers WJ; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Schalken JA
Clin Cancer Res; 2015 Jul; 21(13):3061-70. PubMed ID: 25788493
[TBL] [Abstract][Full Text] [Related]
9. Combining urinary DNA methylation and cell-free microRNA biomarkers for improved monitoring of prostate cancer patients on active surveillance.
Zhao F; Vesprini D; Liu RSC; Olkhov-Mitsel E; Klotz LH; Loblaw A; Liu SK; Bapat B
Urol Oncol; 2019 May; 37(5):297.e9-297.e17. PubMed ID: 30777394
[TBL] [Abstract][Full Text] [Related]
10. Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging.
Bakavicius A; Daniunaite K; Zukauskaite K; Barisiene M; Jarmalaite S; Jankevicius F
Clin Epigenetics; 2019 Aug; 11(1):115. PubMed ID: 31383039
[TBL] [Abstract][Full Text] [Related]
11. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
[TBL] [Abstract][Full Text] [Related]
12. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
[TBL] [Abstract][Full Text] [Related]
14. Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer.
Connell SP; O'Reilly E; Tuzova A; Webb M; Hurst R; Mills R; Zhao F; Bapat B; Cooper CS; Perry AS; Clark J; Brewer DS
Prostate; 2020 May; 80(7):547-558. PubMed ID: 32153047
[TBL] [Abstract][Full Text] [Related]
15. Frequent methylation of RASSF1 and RARB in urine sediments from patients with early stage prostate cancer.
Daniūnaitė K; Berezniakovas A; Jankevičius F; Laurinavičius A; Lazutka JR; Jarmalaitė S
Medicina (Kaunas); 2011; 47(3):147-53. PubMed ID: 21822036
[TBL] [Abstract][Full Text] [Related]
16. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.
Dimitriadis E; Kalogeropoulos T; Velaeti S; Sotiriou S; Vassiliou E; Fasoulis L; Klapsas V; Synesiou M; Apostolaki A; Trangas T; Pandis N
Anticancer Res; 2013 Jan; 33(1):191-7. PubMed ID: 23267145
[TBL] [Abstract][Full Text] [Related]
17. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up.
Johnson H; Guo J; Zhang X; Zhang H; Simoulis A; Wu AHB; Xia T; Li F; Tan W; Johnson A; Dizeyi N; Abrahamsson PA; Kenner L; Feng X; Zou C; Xiao K; Persson JL; Chen L
BMC Med; 2020 Dec; 18(1):376. PubMed ID: 33256740
[TBL] [Abstract][Full Text] [Related]
19. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
[TBL] [Abstract][Full Text] [Related]
20. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies.
Partin AW; Van Neste L; Klein EA; Marks LS; Gee JR; Troyer DA; Rieger-Christ K; Jones JS; Magi-Galluzzi C; Mangold LA; Trock BJ; Lance RS; Bigley JW; Van Criekinge W; Epstein JI
J Urol; 2014 Oct; 192(4):1081-7. PubMed ID: 24747657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]